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Abstract: Since emergence of chloroquine-resistant Plasmodium falciparum and reports of parasite resistance to alterna-
tive drugs, there has been renewed interest in the antimalarial activity of acridines and their congeners, the acridinones. 
This article presents literature compilation of natural acridinone alkaloids and synthetic 9-substituted acridines, acridin-
ediones, haloalcoxyacridinones and 10-N-substituted acridinones with antimalarial activity. The review also provides an 
outlook to antimalarial modes of action of some described compounds. 
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INTRODUCTION 
  Malaria is the most important parasitic disease in the 
world. Its aetiological agents are protozoa of the genus 
Plasmodium. P. falciparum is the most virulent among the 
four species infecting humans and is responsible for most of 
mortality. In 2008, among 3.3 billion people at risk , there 
were 243 million malaria cases, causing an estimated 863 
000 deaths, mostly of children under five years. From 109 
countries endemic for malaria, 45 were within the WHO 
(World Health Organization) African Region [1]. 
  The combination of tools and methods to combat malaria 
now includes only artemisinin-based combination therapy 
(ACT) to treat this infectious disease [1]. Resistance of P. 
falciparum has emerged to all classes of antimalarial drugs 
except artemisinin. Although resistance to artemisinin de-
rivatives has not yet been identified, with increased use of 
these drugs, it is expected that resistant parasites will be se-
lected. 
  The lack of structural diversity of currently used antima-
larials is evident. A small number of chemically related 
drugs belonging to five classes of compounds: 4-
aminoquinolines (chloroquine (CQ), quinine, mefloquine, 
amodiaquine and halofantrine), 8-aminoquinolines (prima-
quine), antifolate compounds, atovaquone and artemisinin 
derivatives are currently in use [2]. Is obvious the urgent 
need for new antimalarials.  
  Acridine and acridinone are chemical families differing 
from most current antimalarials. Several derivatives have   
demonstrated strong antimalarial activity; two of them have 
been clinically tested.  
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 Quinacrine  (QA), 6-chloro-2-methoxy-9-(4-diethy-
lamino-1-methylbuthylamino)acridine  (Fig.  1), was the 
first known clinically tested antimalarial. This 9-
aminoacridine was discovered in 1933 following an inten-
sive search for synthetic quinine substitutes and was used 
when quinine became practically unavailable during World 
War II [3]. Although it is not currently in use as antimalarial, 
this drug has inspired many scientists to design, synthesise 
and evaluate many related derivatives. 
 Pyronaridine (Pyr), (2-methoxy-7-chloro-10-[3´,5´-
bis(pyrrolidinyl-1-methyl) 4´hydroxyphenyl] aminoben-
zyl-(b)-1,5-naphthyridine) (Fig. 1), the other clinically 
tested acridine-based antimalarial, was designed and synthe-
sised at the Institute of Parasitic Diseases, Shanghai, in 1970. 
Clinical trials began in 1971 and nine years later was for-
mally released as a new antimalarial drug in China [4]. Now 
is being used as fixed-dose combination with artesunate 
(PYRAMAX
), for uncomplicated P. falciparum and P. 
vivax malaria as a once a day for three days treatment [5]. In 
2008, four pivotal Phase III trials were completed; the paedi-
atric granular formulation were registered in 2009 
(http://www.mmv.org). 
  Recent structure-activity relationship studies have re-
vealed new promising antimalarials based on acridine and 
acridinone core. Haloalcoxyacridinones, extremmely potent 
antiplasmodial activity in vitro [6], novel acridinedione with 
potent inhibitory activity of mitochondrial bc1 Complex [7], 
and 10-N-substituted acridinones showing strong chemosen-
sitizing properties and heme polymerisation inhibition [8] 
are the most significant structures. 
  This review covers the antimalarial acridine and acridi-
nones from natural and synthetic sources. Information on 
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NATURAL STRUCTURES 
 Acridinone alkaloids are synthesised by plants of Ruta-
ceae  family. Most of these structures have exhibited high 
activity against tumoral cell lines and some of them have 
been tested against malaria parasites.  
 Acronycine  (1, Fig. 2) was first isolated from the Austra-
lian scrub ash Acronychia baueri, it showed antineoplastic 
[9] and antiparasitic activity [10]. The antimalarial activity 
was firstly tested in vitro against Plasmodium yoelii [11]. 
Acronycine and 5-hydroxyacronycine  (2, Fig. 2) sup-
pressed almost 90 % of parasitemia in vitro, however, they 
were moderately active against P. falciparum [12]. Further-
more, many derivatives of this alkaloid were evaluated, only 
2-nitroacronycine (3, Fig. 2) improved the antimalarial ac-
tivity, reaching IC50 values around 2 μg/mL for susceptible 
and resistant strains [12]. 
  Other seven kinds of acridinone alkaloids obtained from 
Rutaceae plants: glycocitrine-I  (4),  des-N-methylnor-
acronycine  (5),  atalaphillinine  (6),  5-hydroxy-N-
methylseverifoline  (7),  atalaphillidine  (8) and glycobis-
mine-A (9), Fig. (2), exhibited antimalarial activity compa-
rable to chloroquine diphosphate using the model of P. yoelii 
described by Fujioka et al. [11]. Atalaphillinine inhibited 
completely the development of malaria parasites in vivo after 
prophylactic administration in a daily dose of 50 mg/Kg for 
3 days with no obvious toxic effect [11]. Forty-seven new 
acridinone alkaloid derivatives were tested for these authors. 
Four compounds exhibited potent antimalarial activity (IC50 
of 23-150 ng/mL) against P. yoelii in vitro [13]. 
 Arborinine  (10, Fig. 2) and normelicopicine, acridinone 
alkaloids isolated from Teclea thiocarpa (Rutaceae: Toddal-
ioideae), posses modest antiplasmodial activity against P. 
falciparum [14]. Normelicopicine caused 32 % parasitemia 
suppression at a dose of 25 mg/Kg [14]. 
  Acronycine-inspired thioacridinones were synthesised for 
evaluation as antitumor agents. The thioacridinones were 
also tested for antimalarial activity against a CQ-sensitive 
strain of P. falciparum; all products showed antiplasmodial 
activity (IC50 0.4-27 μg/ml). The most potent compound, 8-
{[2-(dimethylamino)ethyl]amino}acridine-9(8aH)-thione), 
(11, Fig. 2) also effectively inhibited the resistant strain 
growth [15]. 
SYNTHETIC ACRIDINES  
9-Aminoacridines 
  A strategy for optimising the 9-aminoacridine antimalar-
ial activity has been recently used, that involves the synthesis 
of 6-chloro-2-methoxyacridine derivatives [16-18].  
 Winter  et al. [6] reported strong in vitro antimalarial ac-
tivity for 2-methoxy-6-chloro-9 aminoacridine (12, Fig. 3) 
(IC50 = 18-42 nM) and 3-(6,6,6-trifluorohexyloxy)-6-
chloro9-aminoacridine  (13, Fig. 3) (IC50 = 2.9-10 nM), 
however, moderate IVTI (in vitro therapeutic indexes), lower 
than 100, were developed using murine splenic lymphocytes. 
  Series of 9-aminoacridine derivatives showed significant 
antimalarial activity against CQ-resistant strains with IC50 
values  0.2 μM [18]. More recently, these authors have syn-
thesized new molecules containing the same scaffold [19]. In 
vitro antimalarial evaluation showed that two positive 
charges as well as the 6-chloro and 2-methoxy substituents 
on the acridine ring were required to exert good antimalarial 
activity. Two compounds inhibited the growth of CQ-
susceptible strain with IC50  0.07 μM, the IC50 value was 
lower than CQ for resistant strains. 9-(6-ammonioethyl-
amino)-6-chloro-2-methoxyacridinium dichloride (14, 
Fig. 3) was the most promising agent displaying the lowest 
toxicity against KB cells line, exhibiting moderate selectivity 
indexes ranging from 7 for CQ-resistant strains to 50 for 
susceptible strain. 
9-Anilinoacridines 
  These acridine derivatives have well described biological 
actions and many have been used successfully to treat differ-
ent forms of leukemia [20]. Following the principle of a 
common intracellular target (Topoisomerase II), a series of 
9-anilinoacridines were synthesized with varied acridine ring 
and anilino substituents which showed difference in struc-
ture-activity relationship against P. falciparum [21-23]. Most 
active compounds possess 3,6 diamino substitutions on the 
acridine ring (3,6-diamino-1’-amino-9-Anilinoacridine 
(15, Fig. 3), 1’-dimethylamino-3,6-diamino-9-Anilinoacri-
dine (16, Fig. 3)) exhibiting IC50 values in the low nanomo-
lar range against K1 (CQ-resistant strain) [22, 24]. The over-
all hydrophilicity and the high basicity are important deter-
minants of parasite inhibition. This dependence on hydro-
philic character seems reflect drug penetration factors [22]. 
  Recently, antimalarial evaluation of a series of hybrid 9-
anilinoacridine/ triazine was reported [25]. Two compounds, 
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naphthyridin-10-yl)amino]phenyl}-N
4-[1-dimethylamino) 
propyl]-N
6-phenyl-1,3,5-triazine-2,4,6-triamine (17, Fig. 
3) and N-{6-[(7-chloro-2-methoxy-10,10a-dihydrobenzo-
[b]-1,5-naphthyridin-10-yl)amino]pyridin-3-yl}-6-hydraz-
ino-N'-phenyl-1,3,5-triazine-2,4-diamine (18, Fig. 3) dis-
played two times higher potency than CQ, against a sensi-
tive-strain (IC50 around 4.2 nM) and fairly high selectivity 
index (SI > 295) respect to VERO cells cytotoxicity. How-
ever, no significant protection by oral administration of 100 
mg/Kg of active compounds was obtained in 28 days sur-
vival assay using mice infected with CQ-resistant N-67 
strain of P. yoelii. Other two compounds, N
2-{4-[(7-chloro-
2-methoxy-10,10a-dihydrobenzo[b]-1,5-naphthyridin-10-
yl)-amino]phenyl}-N
4-(2-morpholin-4-ylethyl)-N
6-phenyl-
1,3,5-triazine-2,4,6-triamine (19, Fig. 3) and -N
2-{4-[(7-
chloro-2-methoxy-10,10a-dihydrobenzo[b]-1,5-naphthyri-
din-10-yl)amino]phenyl}-N
4-(4-fluorophenyl)-N
6-(2-mor-
pholin-4-ylethyl)-1,3,5-triazine-2,4,6-triamine (20, Fig. 3), 
less active in vitro, displayed more than 95 % suppression in 
the same in vivo model.  
Other 9-Substituted Acridines 
  Sulfonamide and urea derivatives of QA with varying 
methylen spacer lengths have been tested for in vitro activity 
against CQ-sensitive and resistant strains [26]. One urea de-
rivative, N-benzyl-N'-[4-(7-chloro-2-methoxybenzo[b]-1,5-
naphthyridin-10-yl)butyl]urea (21, Fig. 3), showed potent 
activity against the sensitive strain although low selectivity 
index was obtained.  
  Aryl sulfones and aryl thioacridine were studied in an 
approach to obtain combined functions, QA and sulfonamide 
or sulfone drugs targets, in the same structure [27]. IC50 val-
ues are included from 4 up to > 500 μM for susceptible strain 
and from 6.4 up to > 500 μM for resistant strain. No im-
provement of antimalarial activity was observed. 
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SYNTHETIC ACRIDINONES 
Acridinediones 
  Floxacrine, 7-chloro-10-hydroxy-3-[4-(trifluorome-
thyl)-phenyl]-3,4-dihydroacridine-1,9(2H,10H)-dione (22, 
Fig. 4), is one of a group of dihydroacridinediones, originally 
synthesized searching for novel and effective antibacterial 
drugs [28]. Significant prophylactic antimalarial activity was 
exhibited by this compound [29], but unfortunately, it had 
several liabilities, including limited water solubility [30], 
parasite drug resistance [28, 31] and dose dependent periar-
teritis [31]. 
  Those reasons led to substantial efforts to identify an 
analogue of floxacrine without those drawbacks [30, 32-34]. 
A  QA-Floxacrine, hybrid, WR 243251,  (1E)-7-chloro-3-
(2,4-dichlorophenyl)-1-{[3-(dimethylamino)propyl]imi-
no}-1,3,4,10-tetrahydroacridin-9(2H)-one (23, Fig. 4) [30, 
32], devoid of the vascular cardiotoxicity of floxacrine, 
emerged as potential antimalarial agent.  
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  Recently, other derivatives as WR 249685, 7-chloro-3-
(2,4-dichlorophenyl)-3,4-dihydroacridine-1,9(2H,10H)-di-
one (24, Fig. 4),  WR 243246  S-enantiomer, have shown 
strong antimalarial activity (IC50 ~ 15 nM) and specific in-
hibitory activity of parasite mitochondrial bc1 Complex [7]. 
Haloalcoxyacridinones 
  A novel class of highly active and selective antimalarial 
acridinones (haloalcoxyacridinones) was discovered using an 
empirical design strategy [6]. Firstly, the authors obtained 2-
methoxy-6-chloroacridinone (25, Fig. 4) by mild hydroly-
sis of QA, this compound showed strong in vitro antimalarial 
activity (similar to 2-methoxy-6-chloro-9-aminoacridine 
(12, Fig. 3), IC50 of 45 nM for susceptible strain (D6) and 65 
nM for multidrug resistant strain (Dd2), with higher SI). This 
acridinone was selected as lead to synthesized new ana-
logues to develop a structure activity profile. Thirty com-
pounds were evaluated, 11 acridinones showed IC50 values 
lower than CQ against susceptible (D6) and resistant (Dd2) 
P. falciparum strains. The most potent compounds share a 
unique and defining structural element in the C ring com-
posed of an extended alkyl group terminated by one or more 
trifluoromethyl groups at the 3 position of the tricyclic acri-
done.  3-(5,6,6,6-Tetrafluoro-5-trifluoromethyl-hexyloxy)-
6-chloroacridinone (26, Fig. 4) showed IC50 values  1 pM 
against the two strains and IVTI higher than 100 000 [6]. 
N
Cl
O
OH
O
F
F
F
22
N
H
N N
Cl
O
Cl Cl
23
N
H
Cl
O
Cl
O
Cl 24
N
O
25
Cl
O
N Cl
O
O
F
F
26
F F
F
F
F
N
O
N
O
N
Cl
27
N
O
N
28  
Fig. (4). Antimalarial acridinones (compounds 22- 28). 16    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Aymé Fernández-Calienes Valdés 
10-N-Substituted Acridinones 
  New interesting acridinones were synthesised and tested 
[35]. Alkyl side chains (with lengths ranging from two to 
eight carbons) with tertiary amino group at the terminal posi-
tion were attached at N 10 position of acridinones. Those 
compounds exhibited antimalarial in vitro activity in the M 
range but display CQ-chemosensitizing activities against 
Dd2 strain. More recently, these authors [8] designed, syn-
thesized and tested a dual function acridinones, incorporating 
into one molecule a heme- targeting tricyclic mainframe with 
an ionoizable side chain to promote accumulation in the di-
gestive vacuole and a chemosensitization moiety at the N 10 
position. The lead compound, T3.5, (3-chloro-6-(2-
diethylamino-ethoxy)-10-(2-diethylamino-ethyl)-acridino-
ne), (27, Fig. 4), showed IC50 values in the nM range against 
a panel of CQ-susceptible and resistant strains and proved 
synergistic with chloroquine, amodiaquine (verapamil-like 
chemosensitization) and quinine or piperaquine against Dd2 
strain. In vivo evaluation, using murine malaria parasites (P. 
yoelii and P. berghei) demonstrated a curative action of 256 
mg/Kg/day orally or 200 mg/Kg/day intraperitoneally. No 
overt toxicity or behaviour change was observed in animals. 
MECHANISMS OF ANTIMALARIAL ACTIVITY 
  In order to design and develop new therapies that cir-
cumvent resistance many efforts are dedicated to elucidate 
the mode of action of new synthesised compounds and clini-
cally tested agents which mechanism is not completely clari-
fied, as aminoquinoline and artemisin derivatives [36]. 
  Various mechanisms have been proposed for acridines 
and acridinones with antimalarial action. Inhibition of 
Hemozoin (-hematin) formation, mitochondrial bc1 Com-
plex and DNA Topoisomerase II, and interaction with DNA 
are the widest studied. In addition, acridinone core has been 
recently used to build potent chemosensitizers. 
Inhibition of Hemozoin (-Hematin) Formation 
  Malaria parasite survival is dependant on hemoglobin 
proteolysis. The amino acids derived from globin hydrolysis 
are incorporated into parasite proteins and appear to be 
available also for energy metabolism. Heme moiety is re-
leased as result of hemoglobin digestion. Lacking of heme 
oxygenase, plasmodial species sequester this toxic by-
product into a chemically inert crystal. The product formed, 
hemozoin, is an aggregate of several units of hematin linked 
by carboxylate-iron(III) and carboxylate-carboxylate coordi-
nated bonds. The aggregation process is a mechanism of 
detoxification that has been used as a target for antimalarial 
therapy [37]. Considerable data support the hypothesis that 
antimalarial quinolines inhibit parasite growth by binding to 
hematin preventing its agregation into the form of hemozoin 
[38].  
  Quinolines such as CQ form complexes with hematin in 
solution forming “-” or stacked complexes. Molecular 
planes are approximately parallel and in close proximity. 
Hydrophobic effect has a major influence on the free energy 
of complex formation. But, at the same time electrostatic and 
dispersion interactions are likely important as in other aro-
matic stacking interaction [38]. A previous study postulates 
that electronic features rather than steric factors seem to con-
trol primarily the inhibitory activity against hematin aggre-
gation, concurring to a potential antimalarial activity [39]. 
Antimalarial compounds stabilize the dimer due to the wide 
range interactions determined by their complementary elec-
trostatic profiles avoiding a further aggregation of this unit to 
form hemozoin. The positive potential of the aromatic ring 
of the active compounds would interact with negative poten-
tial on the center of the dimer. The regions of negative po-
tential for the active compounds would stabilize the positive 
potential peripheral to the tetrapyrrol system of the hematin 
complex [39]. 
 QA exhibited IC50 of 41 μM testing its action in -
hematin formation [40]. Other related structures with antima-
larial activity have been also tested. Pyr (Fig. 1) targets he-
matin, as demonstrated by its ability to inhibit in vitro -
hematin formation (at a concentration equal to that CQ) and 
to form a complex with hematin with stoichiometry of 1:2 
[41]. 
  A series of 9-anilinoacridines were investigated for their 
abilities to inhibit -hematin formation and to form drug 
hematin complexes [24]. In general, poor relation between 
inhibition and antimalarial activity was observed, only one 
compound (16, Fig. 3) may exerts its antimalarial activity by 
inhibiting hemozoin formation. 
 WR  243251  (23, Fig. 4) was potent inhibitor of hematin 
polymerization (IC50 = 90 μM, CQ IC50 = 80 μM), however, 
this inhibition did not completely account for the increased 
antimalarial potency versus CQ for resistant strain K1   
(IC50 = 9.5 nM, CQ IC50 = 450 nM) [42]. Floxacrine (22, 
Fig. 4) was 2-fold less potent than CQ for hematin polymeri-
zation inhibition and its analog WR 243246 (24, Fig. 4) was 
without activity indicating that it exerts antimalarial activity 
by other mechanisms [42]. 
  Recently, the affinity of new dihydroacridinediones for 
heme and their ability to inhibit heme crystalization relative 
to known heme-binding drugs were determined [7]. In this 
study, Floxacrine (22, Fig. 4) inhibited heme crystalization 
with similar IC50 value that CQ whereas WR 249685 (24, 
Fig. 4) exhibited two-fold lower activity. Heme-drug equilib-
rium constants were calculated to be; 1.38 μM for CQ, 1.87 
μM for Floxacrine  (22, Fig. 4) and 31.7 μM for WR 
249685. The relative poor heme binding affinity of WR 
249685 (22, Fig. 4) was in contrast to its potent in vitro an-
timalarial activity (IC50 15 nM), this result suggest a differ-
ent mechanism to exert the antimalarial action. 
  The dual function acridinone T3.5 (27, Fig. 4) interacts 
with heme to form a soluble complex with strong affinity at 
pH 5.2. This compound interferes with hemozoin, decreasing 
intracellular pigment incorporated during 24 hours per para-
sitized erythrocyte with susceptible and resistant strains. 
Visual localization of acridinone inside the P. falciparum-
infected erythrocyte by confocal fluorescence microscopy 
indicates uptake and accumulation within the digestive 
vacuole [8]. 
  Few studies about structure-inhibitory activity relation-
ship for acridine and acridinone derivatives have been done. 
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line ring appears to be crucial in determining the ability to 
inhibit hemozoin formation, the presence of a chlorine atom 
at this position is an indicative of activity (43). QA (Fig. 1), 
Pyr (Fig. 1) and the dual function acridinone T3.5 (27, Fig. 
4) contain the related chlorine group. In addition, the ami-
noalkyl side chain plays a relevant role on quinoline inhibi-
tory activity [44]. QA (Fig. 1), Pyr (Fig. 1) and WR243251 
(23, Fig.4) possess an aminoalkyl side chain also, in contrast, 
low inhibition was observed testing WR 243246 (24, Fig. 4) 
[42] and its S-enantiomer WR 249685 (24, Fig. 4) [7] which 
do not contain that moiety. Tricycle mainframe with an ioni-
zable side chain were designed to guaranteed heme-targeting 
of dual function acridinones, promoting accumulation in the 
digestive vacuole [8]. 
Inhibition of Mitochondrial bc1 Complex 
  In most eukaryotic cells, the mitochondrial electron 
transport chain (mtETC) is required for generation of the 
proton motive force, which is central to oxidative energy 
metabolism. However, in organisms or under conditions fa-
voring a glycolytic metabolism, which include the blood 
stages of malaria parasite, the role of the mtETC is often 
reduced, and mitochondria may even become consumers 
rather than producers of energy (reviewed in Reference 45). 
Despite the relatively low activity of the mtETC in malaria 
parasites it still appears to be the primary source of the mito-
chondrial proton electrochemical gradient. Furthermore the 
sensitivity of parasites to inhibitors of the mtETC indicates 
that it is indispensable to the parasites [45]. 
 The  bc1 Complex (mitochondria Complex III) is a mem-
brane-bound enzyme catalyzing the transfer of electrons 
from ubiquinol to cytochrome c coupled with the concomi-
tant vectorial translocation of protons across the inner mito-
chondrial membrane [46]. The catalytic core of the enzyme 
is made up cytochrome b, cytochrome c1 and the Ruske iron-
sulfur protein (ISP). The catalytic mechanism, known as the 
Q-cycle [46, 47] involves two distinct quinone binding sites 
within cytochrome b, the quinol oxidation site Qo and the 
quinone reduction site Qi [46]. These two sites are situated 
on opposite sides of the membrane linked by trans-
membrane electron pathway via hemes b1 and bh. A number 
of inhibitors selective for bc1Qo and Qi sites have been de-
veloped to control human pathogens. 
  Antimalarial drug atovaquone targets the Qo of cyto-
chrome  b in Plasmodium and related parasites [48]. WR 
243251 (23, Fig. 4) exhibited cross resistance with atova-
quone [49]. It reduced the rate of parasite oxygen consump-
tion by almost 80% in the atovaquone-sensitive isolate and 
by 57 % in the atovaquone-resistant isolate. Drug interaction 
studies suggest that atovaquone and WR 243251 (23, Fig. 4) 
may inhibit growth additively or with mild synergy. To-
gether these results suggest that while WR 243251 (23, Fig. 
4) inhibits respiration, its mitochondrial target probably dif-
fer from that of atovaquone, besides, haem polymerization 
inhibition could be a further mechanism of action for this 
compound (see above). 
 Biagini  et al. [7] investigated the antimalarial mode of 
action of other two different dihydroacridinediones, Flox-
acrine (22, Fig. 4) and WR 249685 (24, Fig. 4). Both of 
these compounds showed heme binding and bc1 inhibitory 
properties. However, whereas Floxacrine (22, Fig. 4) exhib-
ited the most potent heme polymerization inhibition, WR 
249685 (24, Fig. 4) is shown to be a highly species selective 
inhibitor of the Qo at the P. falciparum bc1. Last acridinedi-
one displayed a Ki for P. falciparum of 0.3 nM and in vitro 
therapeutic index against human bc1 of > 4600. Docking of 
WR 249685 (24, Fig. 4) to the P. falciparum bc1 model was 
energetically favourable, the model demonstrated selectivity 
in the docking of traditional Qo and Qi inhibitors. The most 
stricking feature of the model for dihydroacridinedione was 
the putative association between the inhibitor and the E-ef 
linker region of the cytochrome, a region of low sequence 
identity between P. falciparum and mammalian cytochrome 
b. 
Interaction with DNA 
  Planar structure of tricycle rings confers to derivatives 
the ability to intercalate in the DNA and interfere with vari-
ous metabolic processes both in procaryotic and eukaryotic 
cells.  
  This is the proposed mechanism of antitumoral activity 
for some acronycine analogues. The most potent antimalarial 
thioacridone also binds to DNA but no correlation seems to 
be apparent between IC50 value and DNA binding constant 
[50]. 
  Depending on the nature of a particular compound and its 
substituents, the results and cellular consequences of 
acridine-DNA interaction may vary significantly [51, 52]. 
  9-aminoacridines based structures (including QA, Fig. 1) 
are DNA-binding small molecules that do not induce DNA 
damage [53]. The interaction of QA (Fig. 1) with DNA was 
firstly reported by Van Dyke et al. [54]. They observed yel-
low-green fluorescence in nuclei of parasite P. falciparum in 
the presence of that acridine. In the course of mechanistic 
studies of QA (Fig. 1), it was noted that no inmediate con-
nection between DNA interaction and therapeutic capacities 
was stablished [53]. New mechanisms have been discovered 
for QA (Fig. 1) and 9-aminoacridine derivatives in cancer 
cells. This compounds inhibited NFk B-mediated transcrip-
tion and HSF1-mediated HSR [54, 55]. In the last study the 
authors hypothesised that the drugs may be effective in ma-
laria inhibiting HSP synthesis, thereby sensitizing P. falcipa-
rum to fever induced by the host (e.g., heat shock) [55]. 
  Antimalarial 9-anilinoacridines developed different 
ranges of DNA binding, Pyr (Fig. 1) also binds to DNA 
showing a concentration of 0.17 μM to displace 50 % of the 
bound ethidium from calf thymus DNA. In general, no corre-
lation with parasiticidal action was observed [22]. Available 
evidences support a model whereby the acridine moiety in-
tercalates into DNA and the 9-anilino side group projects 
into the DNA minor groove where it interacts with topoi-
somerases in cancer cells. The most widely and successfully 
used anticancer agents are the nonspecific DNA-damaging 
chemicals, including topoisomerases inhibitors [53]. Am-
sacrine (antitumoral acridine with moderate antimalarial ac-
tivity) inhibit Topoisomerase II activity and alkylate DNA 
providing DNA damage [53]. 18    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Aymé Fernández-Calienes Valdés 
Topoisomerase II Inhibition 
  Topoisomerases are essential for the modification of to-
pology of nucleic acids. DNA topoisomerases are divided 
into two types: type I enzyme breaks one DNA strand for the 
passage of a second strand and the type II enzyme breaks 
both strands of one DNA duplex for the passage of a second 
DNA double strand [56].  
  The antimalarial compound 15 (Fig. 3) and the drug Pyr 
(Fig. 1) inhibited the decatenation activity of P. falciparum 
DNA topoisomerase II at concentration of 10 and 11 M, 
respectively [22]. 
  DNA cleavage is a transesterification reaction, and a co-
valent protein-DNA intermediate is formed during the tran-
sient DNA cleavage stage. This covalent topoisomerse II-
DNA complex can be trapped in vitro by the addition of a 
protein denaturing such as sodium duodecyl sulphate (SDS) 
and is termed a cleavable complex [56]. 
  The ability to generate in situ enzyme-DNA adducts or 
cleavable complexes by series of 9-anilinoacridines with 
antimalarial activity were examined [56]. 9-anilinoacridine 
derivatives with 3,6-diamino substituents produced protein-
DNA complexes, whereas, Pyr (Fig. 1) did not generate it.  
Chemosensitization 
  Chemosensitizers are compounds capable to reverse re-
sistance, they lower the IC50 values of drugs against resistant 
parasites strains. Verapamil, a calcium channel blocker, was 
the first P. falciparum CQ-resistant reversal agent discovered 
[57]. Since then, many structurally and functionally diverse 
compounds have been identified and reported to demonstrate 
chemosensitization activity against malaria parasite, with 
antihistamines (e.g., chlorfeniramine) and tricyclic antide-
pressants (e.g., desipramine) among the most effective and 
best studied [58, 59]. 
  CQ is a diprotic weak base, neutral and protonated spe-
cies proportion varyies with pH. The neutral species enters 
the parasite and its internal compartments via simple difus-
sion. Acidic enviroment of parasite´s digestive vacuole, in-
crease the proportion of diprotonated CQ, which is unable to 
diffuse across the membrane and becomes trapped [60]. A 
recent study [60] demonstrated that chloroquine resistance is 
due to direct transport of the drug, out of the vacuole, and 
thus away from its site of action, via mutant CQ resistance 
transporter (PfCRT). 
  Mutations in the PfCRT protein, particularly the re-
placement of a lysine (K) with a threonine (T) at position 76, 
may play key roles in the mode of action of verapamil [61]. 
This K76T mutation occurs in a region of the protein that is 
predicted to be involved in substrate recognition [62]. The 
presence of a positive charge in the PfCRT substrate-binding 
site prevents protonated-CQ from interacting with the trans-
porter [60]. Verapamil inhibited the transport of CQ via 
PfCRT (resistant phenotype) showing half-maximum inhibi-
tory concentration of 30 ± 3 μM, as did a range of quinolines 
including quinine and amodiaquine. Hydrogen bond acceptor 
and two hydrophobic aromatic rings define the basic ele-
ments involved in interactions between PfCRT (resistant 
phenotype) and substrates or inhibitors [60].  
  Chemosensitizing acridinones were designed based on 
the critical features for CQ-chemosensitizing activity already 
mentioned (hydrogen bond acceptor and two hydrophobic 
aromatic rings). Firstly, Kelly et al. [35], synthetized and 
evaluated a series of 10-N-substituted acridinones bearing 
alkyl side chains with tertiary amino groups. The most potent 
CQ-chemosensitizer compound KF-A, 10-[6-(diethyl-
amino)hexyl]acridin-9(10H)-one 28, Fig. 4, potentiated the 
antimalarial activity of CQ more than 80-fold in the Dd2 
strain to a level (19 nM) similar to that observed for CQ-
sensitive strain D6 (14,7 nM). CQ-chemosensitization effect 
was higher than those observed for verapamil and chlor-
feniramine. Isobolar analysis of drug interactions revealed 
significant synergy. As was expected, acridinone bearing the 
N-10 alkyl chain but terminated with a chlorine atom, in-
stead of terminal amino group, was without chemosensitiza-
tion activity.  
  Later, the same authors, reported the discovery of the 
dual function acridinones which include, besides haem tar-
geting structure, a chemosensitization moiety at the N10 
position [8]. The most potent compound, T3.5 (27, Fig. 4), 
proved synergistic with chloroquine, amodiaquine, quinine 
or piperaquine but not with mefloquine against Dd2 strain. 
As was expected for verapamil-like chemosensitizers, no 
synergy between CQ and T3.5 (27, Fig. 4) was obtained for 
sensitive strain. Different behaviour, unlike verapamil, was 
observed for quinine synergy and PfCRT interaction, no ex-
planation was established for those results. 
  The clinical utility of tricyclic antidepressants and anti-
histamine compounds as antimalarial chemosensitizers is 
limited by adverse effects at the high doses required for 
chemosensitizing efficacy. Since the antidepressants are be-
lieved to inhhibit neurotransmite uptake by the biogenic 
amine transporters and the antihistamine act by competing 
with histamine for H1 receptor sites on efector cells [35]. 
Although structural similarities between chemosensitizers 
acridinones and tricyclic antidepressants, no significant af-
finity with serotonin, dopamine or noradrenaline transporters 
was observed [35, 8]. 
CONCLUSIONS 
  Acridinone alkaloids represent the acridinone based 
structures with antimalarial activity isolated from natural 
sources. A few of those alkaloids have shown strong and 
selective antiplasmodial activity and have motivated synthe-
sis of new structures. Several acridine and acridinone deriva-
tives with antimalarial activity have been synthesised in-
spired by quinacrine (QA) and pyronaridine (Pyr) structures. 
Although recent studies have revealed potent acridine-based 
structures against susceptible and resistant strains, selectivity 
indexes remains moderated. The number of studies on syn-
thetic antimalarial acridinones is low but this chemical fam-
ily includes the most promising new compounds obtained so 
far. Inhibitory concentration fifty in the nanomolar range and 
selectivity indexes of thousands are the most relevant fea-
tures. The most potent compounds exert their antimalarial 
action inhibiting hemozoin formation or mitochondrial bc1 
Complex activity. Acridine and Acridinones with Antimalarial Activity  The Open Medicinal Chemistry Journal, 2011, Vol. 5    19 
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